Synovia Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.95 M
as on 18-07-2024
- Paid Up Capital ₹ 0.90 M
as on 18-07-2024
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 7.08 M
as on 18-07-2024
- Revenue 25.11%
(FY 2022)
- Profit 8.09%
(FY 2022)
- Ebitda 11.67%
(FY 2022)
- Net Worth 23.26%
(FY 2022)
- Total Assets 12.92%
(FY 2022)
About Synovia Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.95 M and a paid-up capital of Rs 0.90 M.
The company currently has active open charges totaling ₹7.08 M.
Satish Sharma, Anoop Chauhan, Ramesh Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24232RJ2009PTC028974
- Company No.
028974
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Synovia Life Sciences?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satish Sharma  | Director | 26-May-2009 | Current |
| Anoop Chauhan | Director | 26-May-2009 | Current |
| Ramesh Shah | Director | 26-May-2009 | Current |
| Nitin Verma | Director | 01-Aug-2022 | Current |
| Bharat Jain | Director | 14-Sep-2009 | Current |
Financial Performance and Corporate Structure Insights of Synovia Life Sciences.
Synovia Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 25.11% increase. The company also saw a slight improvement in profitability, with a 8.09% increase in profit. The company's net worth Soared by an impressive increase of 23.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Synovia Life Sciences?
In 2021, Synovia Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
5 years 2 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 Apr 2023 | ₹1.05 M | Open |
Hdfc Bank Limited Creation Date: 14 Jun 2021 | ₹1.20 M | Open |
Hdfc Bank Limited Creation Date: 28 Feb 2021 | ₹1.20 M | Open |
How Many Employees Work at Synovia Life Sciences?
Synovia Life Sciences has a workforce of 76 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Aug 01, 2012, Synovia Life Sciences has raised a total of ₹ 1.6 M, with the most recent deal valued at ₹ 0.8 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
